240 related articles for article (PubMed ID: 29978334)
1. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
Mishra HK; Pore N; Michelotti EF; Walcheck B
Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
[TBL] [Abstract][Full Text] [Related]
2. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
3. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
Wu J; Mishra HK; Walcheck B
J Leukoc Biol; 2019 Jun; 105(6):1297-1303. PubMed ID: 30786043
[TBL] [Abstract][Full Text] [Related]
4. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.
Lajoie L; Congy-Jolivet N; Bolzec A; Gouilleux-Gruart V; Sicard E; Sung HC; Peiretti F; Moreau T; Vié H; Clémenceau B; Thibault G
J Immunol; 2014 Jan; 192(2):741-51. PubMed ID: 24337742
[TBL] [Abstract][Full Text] [Related]
5. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.
Jing Y; Ni Z; Wu J; Higgins L; Markowski TW; Kaufman DS; Walcheck B
PLoS One; 2015; 10(3):e0121788. PubMed ID: 25816339
[TBL] [Abstract][Full Text] [Related]
6. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
7. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
8. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
Matson AW; Hullsiek RH; Dixon KJ; Wang S; Lindstedt AJ; Friess RR; Phung SK; Freedman TS; Felices M; Truckenbrod EN; Wu J; Miller JS; Walcheck B
bioRxiv; 2024 May; ():. PubMed ID: 38798522
[TBL] [Abstract][Full Text] [Related]
9. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
10. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
11. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
[TBL] [Abstract][Full Text] [Related]
12. Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils.
Snyder KM; McAloney CA; Montel JS; Modiano JF; Walcheck B
Vet Immunol Immunopathol; 2021 Jan; 231():110162. PubMed ID: 33264689
[TBL] [Abstract][Full Text] [Related]
13. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
14. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
15. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
16. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
[TBL] [Abstract][Full Text] [Related]
17. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
Parihar R; Trotta R; Roda JM; Ferketich AK; Tridandapani S; Caligiuri MA; Carson WE
Cancer Res; 2005 Oct; 65(19):9099-107. PubMed ID: 16204085
[TBL] [Abstract][Full Text] [Related]
18. Blocking ADAM17 Function with a Monoclonal Antibody Improves Sepsis Survival in a Murine Model of Polymicrobial Sepsis.
Mishra HK; Ma J; Mendez D; Hullsiek R; Pore N; Walcheck B
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932701
[TBL] [Abstract][Full Text] [Related]
19. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
20. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
